

Aurigene inks drug discovery partnership with EQRx

05 July 2022 | News

The parties would share both funding for the discovery and development of the programmes



Aurigene Discovery Technologies, a wholly owned subsidiary of Dr. Reddy's Laboratories, has announced drug discovery, development and commercialisation partnership with US-based EQRx.

The collaboration combines Aurigene's small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.

Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development and commercialisation.

Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialisation efforts. The parties would share both funding for the discovery and development of the programmes and financials resulting from the commercialization of any eventual drug candidates.